Project Grant R01AI179709
Award Date
8/1/24
Completion Date
7/31/29
Dollars Obligated
$815K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Mayo Clinic (Y2K4F9RPRRG7)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Rochester, MN 55905, USA
Similar Awards
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $745,752 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Mayo Clinic. The funding supports research to develop an HIV-1 vaccine that can generate strong immune responses at mucosal surfaces, the primary sites of HIV exposure. Key aspects of the project include: Evaluating the ability of a "single-cycle" adenovirus (SC-AD) vaccine platform to amplify antigen production...
This Cooperative Agreement award for $2,380,350 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund research at Washington University to study the mechanisms of broadly protective immune responses against respiratory viruses, including SARS-CoV-2 and influenza. The two main goals are: (A) defining the mechanisms of germinal center persistence after vaccination and how that impacts long-lived...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $563,588 to Weill Medical College of Cornell University to study the effects of immunosuppression on SARS-CoV-2 persistence, virus genetic diversity, and clinical outcomes of COVID-19. The research aims to determine the immune defects linked to prolonged SARS-CoV-2 replication in immunocompromised hosts, and...
This $380,320 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support research by the Trustees of the University of Pennsylvania to elucidate the lineage dynamics of optimal human CD8 T cell responses to SARS-CoV-2 and how CD8 T cell homeostasis is altered in Long COVID. The key products of this 3-year project include: Defining human memory CD8 T cell differentiation...
The federal Project Grant award of $582,618 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Ohio State University. The goal of the 5-year project is to determine the mechanisms by which RNA modifications, specifically N6-methyladenosine (m6A) and pseudouridine (Ψ), modulate SARS-CoV-2 replication, gene expression, immunity, and pathogenesis. The research will use CRISPR-Cas9...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $188,544.00 to The University of Iowa to conduct research aimed at understanding the role of the SAMHD1 protein in regulating SARS-CoV-2 infection and innate immune responses. The key objectives are to examine how SARS-CoV-2 infection impacts SAMHD1 phosphorylation and its effects on inflammation in primary human...
This federal Project Grant award of $192,888 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports research to evaluate the generation, differentiation, breadth, and persistence of SARS-CoV-2-specific CD4+ and CD8+ T cell responses in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL) patients after vaccination and infection. The goal is to provide in-depth knowledge of...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, provides $705,557 to Emory University from December 20, 2024 to November 30, 2029. The project aims to advance understanding of the coordinated innate and cellular mucosal immune responses that contribute to SARS-CoV-2 viral clearance, particularly in the upper respiratory tract. Key objectives include determining the role of...
This Project Grant award of $190,058 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to define the role of the protein ADAM9 in the immune response to SARS-CoV-2 infection and its impact on lung injury in severe COVID-19 cases. The research will be conducted at the University of Massachusetts Medical School and builds on the candidate's previous work on the ADAM9/MDA5 innate immune pathway. The findings are expected...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $668,569.00 to characterize and optimize a novel genetic vaccine platform called PARVAX. The key objectives are to: Investigate the mechanism behind the potency and durability of the PARVAX platform, hypothesized to be correlated with antigen expression kinetics. Use rational engineering approaches to enhance...